Breo Ellipta is a bronchodilator used to treat pulmonary diseases in the form of inhalation. The active ingredients of this medicine are fluticasone, a corticoid, and vilanterol, a bronchodilator. These substances act in the reduction of inflammation and relaxation of the respiratory muscles.Breo Ellipta is sold as an inhalation powder and is produced by the pharmaceutical laboratory GlaxoSmithKline.
Indications of Breo Ellipta
Breo Ellipta is indicated for the treatment of maintenance of airway obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and / or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
How to use Breo Ellipta
The method of use of Breo Ellipta consists of an inhalation, once a day, exclusively by the oral route. After inhalation, the patient should rinse the mouth with water, without swallowing, to help reduce the risk of oropharyngeal candidiasis.
The Breo Ellipta should be taken at the same time every day. Do not use Breo Ellipta more than once every 24 hours.
Brel Ellipta Side Effects
The most common side effects are nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis.
Contraindication of Breo Ellipta
Breo Ellipta is contraindicated in patients with hypersensitivity to milk proteins, or who have demonstrated hypersensitivity to any component of the formula. It is not indicated for the treatment of asthma.
In what forms Breo Ellipta Is Avaliable
This medication is available in two strips of metal foil wrappers. On one of the strips, each blister pack contains a mixture of dry white powder of micronized fluticasone furoate equivalent to 100 μg and lactose monohydrate for inhalation. On the other strip, each blister pack contains a mixture of dry white powder of micronized vilanterol trifenate equivalent to 25 μg of vilanterol, magnesium stearate and lactose monohydrate for administration by inhalation.